Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors?

The article compares two healthcare ETFs: XBI has a higher 1-year return of 62.9% versus 42.0% for IHE, but also much higher beta at 1.12 and a 5-year max drawdown of 54.7% versus 16.0% for IHE. IHE offers the higher dividend yield at 1.62% versus 0.32%, but is more concentrated, with Eli Lilly and Johnson & Johnson making up 45% of assets. Overall, the piece is a risk/return comparison rather than a catalyst-driven market event.

Analysis

The important read-through is not “pharma beats biotech” but that the market is paying up for cash-flow durability while leaving a lot of dispersion inside healthcare. A low-volatility, dividend-supported wrapper with extreme single-name concentration behaves more like a large-cap stock basket than a true sector fund, so the apparent safety can disappear quickly if one mega-weight stumbles or faces policy pressure.

That creates a hidden catalyst stack around JNJ and RPRX-like capital-return names: they can remain relative winners even if the broader healthcare tape weakens, because investors are likely to keep rotating toward balance-sheet quality and payout visibility in a late-cycle, rate-sensitive environment. Meanwhile, the equal-weight biotech basket is effectively a call option on clinical readouts and M&A; if financing conditions ease or big pharma needs replenishment of pipelines, the beta can reprice higher very fast over a 3-12 month window.

The contrarian point is that the “stable” ETF may be the more crowded trade. If sentiment shifts toward growth and away from defensives, IHE’s concentration becomes a disadvantage rather than a feature, while XBI’s breadth gives it more embedded upside optionality from any broad biotech bid. The better question is whether investors want income today or convexity to the next biotech risk-on phase; they likely can’t own both exposures through the same lens.

Key Decisions for Investors

• Pair trade: long XBI / short IHE over the next 3-6 months if you expect a risk-on shift in healthcare; target is relative multiple expansion in biotech, with stop-loss if large-cap defensives regain leadership.
• Buy JNJ on dips as a defensive quality anchor for 6-12 months; the setup favors capital return and lower drawdown, but size it modestly because concentration risk can still create ETF-level dislocations.
• Own a small basket of TGTX/ALKS/TVTX as a biotech optionality basket for 6-18 months; upside is event-driven and asymmetric, but position sizing should assume binary drawdown risk.
• If you need healthcare exposure but dislike ETF concentration, prefer direct names over IHE; you avoid paying for an index that is economically driven by a few mega-caps.
• Use call spreads on XBI into catalyst windows rather than outright equity if you want convex exposure with defined downside; this is the cleaner way to express a biotech rebound than owning the whole basket outright.